Cellectis S.A. (CLLS) Financials
CLLS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 209.7 million | 133.6 million |
2023-06-30 | 227.7 million | 131.1 million |
2023-03-31 | 251.4 million | 130.9 million |
2022-12-31 | 261.2 million | 135.3 million |
CLLS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -17.4 million | -2.7 million |
2023-06-30 | -19.3 million | 1.6 million |
2023-03-31 | -28.5 million | 1.6 million |
2022-12-31 | 1.7 million | -2.7 million |
CLLS Net Income
No data available :(
CLLS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 67.4 million | - | 52.0 million |
2023-06-30 | 85.5 million | - | 54.4 million |
2023-03-31 | 88.2 million | - | 56.5 million |
2022-12-31 | 97.7 million | - | 57.2 million |
CLLS Shares Outstanding
CLLS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 314000 | 18.9 million | 1.6 million | - |
2023-06-30 | 270000 | 22.1 million | 2.7 million | 1.3 million |
2023-03-31 | 213000 | 21.1 million | 2.1 million | 728000 |
2022-12-31 | 2.9 million | 21.4 million | 17.7 million | 16.0 million |
CLLS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 155000 | 181000 |
2023-06-30 | 178000 | 55000 |
2023-03-31 | 139000 | 334000 |
2022-12-31 | 16.0 million | 690000 |
CLLS
Price: $2.99
52 week price:
Earnings Per Share: -1.41 USD
P/E Ratio: -2.13
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.9 million
Ebitda: -29.3 millionMarket Capitalization: 193.0 million